LivaNova Says CMS Maintains VNS Therapy For DRE At Level 5 APC Under 2025 Medicare Hospital Outpatient Prospective Payment System; Co Will Continue To Pursue Reimbursement Opportunities For VNS Therapy For DRE
Portfolio Pulse from Benzinga Newsdesk
LivaNova announced that the Centers for Medicare & Medicaid Services (CMS) will maintain VNS Therapy for drug-resistant epilepsy (DRE) at Level 5 Ambulatory Payment Classification (APC) under the 2025 Medicare Hospital Outpatient Prospective Payment System. LivaNova will continue to seek reimbursement opportunities for this therapy.
November 01, 2024 | 10:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LivaNova's VNS Therapy for DRE will continue to be classified at Level 5 APC under the 2025 Medicare Outpatient Payment System, which may stabilize reimbursement rates. The company is also seeking additional reimbursement opportunities.
The maintenance of VNS Therapy at Level 5 APC ensures continued reimbursement at a stable rate, which is positive for LivaNova's revenue from this therapy. The company's efforts to pursue additional reimbursement opportunities could further enhance revenue potential.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90